Streetbeat News

Stock Prices

RTX

RTX shares are trading higher following a Q2 earnings beat.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:17 pm

SNY

Sanofi shares are trading higher following a Q2 earnings beat.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:17 pm

NOC

Northrop Grumman shares are trading higher after the company reported a Q2 earnings beat and raised its guidance.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:16 pm

BTI

British American Tobacco shares are trading higher following H1 earnings.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:16 pm

MARA

Marathon Digital Holdings (MARA) has purchased $100 million worth of Bitcoin, bringing its total holdings to over 20,000 BTC.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:09 pm

HAS

Hasbro Inc. (NASDAQ: HAS) reported better-than-expected Q2 FY24 earnings, with a sales decline of 18% year-on-year to $995.30 million, beating the analyst estimate of $943.56 million. Despite a slump in the Entertainment segment, the company saw a significant increase in operating margin and adjusted EBITDA. Hasbro revised its FY24 outlook positively, leading to a 6% rise in its share price.

Portfolio Pulse from Shivani Kumaresan

July 25, 2024 | 12:08 pm

RELX

RELX (NYSE:RELX) reported a 7.14% increase in quarterly earnings per share (EPS) to $0.75, up from $0.70 YoY. Sales also rose by 4.00% to $5.86 billion, compared to $5.63 billion in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:08 pm

CHPT

ChargePoint has expanded its EV charging network to over one million locations across North America and Europe, facilitating more than 10 billion electric miles to date.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:07 pm

AROW

Arrow Financial (NASDAQ:AROW) reported Q2 earnings per share (EPS) of $0.52, missing the analyst consensus estimate of $0.54 by 3.7%. Despite the miss, this represents a 48.57% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:06 pm

VRDN

Viridian Therapeutics has completed enrollment for its THRIVE-2 phase 3 clinical trial for VRDN-001 in patients with chronic Thyroid Eye Disease (TED), exceeding its target with 188 patients. Topline data for THRIVE-2 is expected by year-end 2024, while data for the THRIVE trial is expected in September 2024.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:05 pm